Targeting Bacterial Central Metabolism for Drug Development

Mitochondrial Targeting for Drug Development

Current Trends in Development of Liposomes for Targeting Bacterial Biofilms

Biofilm targeting represents a great challenge for effective antimicrobial therapy. Increased biofilm resistance, even with the elevated concentrations of very potent antimicrobial agents, often leads to failed therapeutic outcome. Application of biocompatible nanomicrobials, particularly liposomally-associated nanomicrobials, presents a promising approach for improved drug delivery to bacteria...

Drug development targeting Mycobacterium tuberculosis signaling

A role for central carbon metabolism in mammalian embryonic development?

Background Embryonic development is not regulated solely by genetic programs but also by metabolic state and environmental cues, which can impact on gene function. Metabolism can influence gene function both canonically (providing substrates for posttranslational modifications etc.) and non-canonically for example via moonlighting enzymes. Moonlighting enzymes have functions in addition to thei...

Targeting the mycobacterial envelope for tuberculosis drug development.

The bacterium that causes tuberculosis, Mycobacterium tuberculosis, possesses a rather unique outer membrane composed largely of lipids that possess long-chain and branched fatty acids, called mycolic acids. These lipids form a permeability barrier that prevents entry of many environmental solutes, thereby making these bacteria acid-fast and able to survive extremely hostile surroundings. Antit...